Search

Guardant Health Inc

Gesloten

SectorGezondheidszorg

170.69 1.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

168.5

Max

170.69

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.1M

-120M

Verkoop

33M

335M

EPS

-0.89

Winstmarge

-35.866

Werknemers

2,490

EBITDA

-8.1M

-109M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+12.23% upside

Dividenden

By Acuity

Volgende Winsten

28 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4B

22B

Vorige openingsprijs

168.89

Vorige sluitingsprijs

170.69

Nieuwssentiment

By Acuity

50%

50%

150 / 340 Rangschikking in Healthcare

Guardant Health Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2026, 19:16 UTC

Guardant Health Inc shares are higher today, despite pulling back from an intraday high. The stock remains well above its 20-day moving average.

20 aug 2026, 23:46 UTC

Guardant Health Inc. shares advanced in after-market trading, remaining above their 20-day moving average amid broader market pressures from rising crude oil prices.

19 aug 2026, 20:02 UTC

Guardant Health Inc shares are higher today, supported by high trading volume. The stock remains above its 20-day moving average and near recent highs.

14 aug 2026, 19:36 UTC

Guardant Health Inc shares are lower amid broader market sentiment following disappointing retail sales data, which may impact consumer demand and Federal Reserve interest rate policy.

13 aug 2026, 23:36 UTC

Guardant Health shares are higher in after-market trading, though no specific news was identified. Broader market sentiment may be influenced by unchanged producer prices.

12 aug 2026, 19:51 UTC

News

Guardant Health shares are lower as insider sales raise investor concerns. Director Ian Clark sold 14,180 shares for $2.3 million earlier this month.

10 aug 2026, 19:36 UTC

Guardant Health Inc. shares are higher today, remaining above their 20-day moving average amid rising oil prices driven by geopolitical tensions.

7 aug 2026, 20:03 UTC

Guardant Health Inc shares are advancing amid strong momentum and high trading volume. Broader market gains coincide with a decline in Treasury yields.

6 aug 2026, 19:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

3 aug 2026, 19:56 UTC

News

Guardant Health shares are higher as Stifel and Canaccord maintain Buy ratings, raising price targets to $180 and $205, respectively.

31 jul 2026, 19:51 UTC

News
Social Media

Guardant Health Inc shares are trading higher as analysts raise price targets following strong second-quarter results and an upward revision of full-year revenue guidance.

30 jul 2026, 23:21 UTC

News
Social Media

Guardant Health reported second-quarter revenue of $335 million, raising 2026 guidance to $1.34 billion to $1.36 billion, boosting shares in after-market hours.

29 jul 2026, 18:54 UTC

Macro Event
News

Guardant Health Inc shares are higher as investors anticipate Q2 earnings on Thursday, following last quarter's revenue of $301.7 million, up 48.3% year-over-year.

28 jul 2026, 19:16 UTC

News

Guardant Health shares are lower despite a tribute video featuring Patrick Dempsey and RBC's note on potential coverage tailwinds for the company.

27 jul 2026, 19:36 UTC

News

Guardant Health Inc shares are lower, continuing a five-day decline despite a 48% year-over-year revenue increase and strong performance in the Shield segment.

24 jul 2026, 18:36 UTC

Guardant Health Inc shares are lower today, continuing a decline since Thursday's close and remaining below the 20-day moving average.

20 jul 2026, 20:02 UTC

News

Guardant Health Inc shares are lower today, continuing a decline since Friday amid mixed U.S. market performance and ongoing geopolitical tensions impacting investor sentiment.

Peer Vergelijking

Prijswijziging

Guardant Health Inc Prognose

Koersdoel

By TipRanks

12.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 191.56 USD  12.23%

Hoogste 215 USD

Laagste 125 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Guardant Health Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

21

Buy

0

Hold

0

Sell

Sentiment

By Acuity

150 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat